Evidence map›Paper›PMID 34938718›Full record

ArticleFrontiers in chemistry2021

Comparison of Three Complementary Analytical Techniques for the Evaluation of the Biosimilar Comparability of a Monoclonal Antibody and an Fc-Fusion Protein.

Alice Demelenne, Arij Ben Yahia, Delphine Lempereur, Jacques Crommen, Anne-Catherine Servais, Ines Fradi, Marianne Fillet

Open access · goldAbstract read
In one paragraph

Article in Frontiers in chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Alice DemelenneLaboratory for the Analysis of Medicines, Center for Interdisciplinary Research on Medicines (CIRM), Quartier Hôpital, University of Liege, Liege, Belgium.
Arij Ben YahiaLaboratory for the Analysis of Medicines, Center for Interdisciplinary Research on Medicines (CIRM), Quartier Hôpital, University of Liege, Liege, Belgium.
Delphine LempereurLaboratory for the Analysis of Medicines, Center for Interdisciplinary Research on Medicines (CIRM), Quartier Hôpital, University of Liege, Liege, Belgium.
Jacques CrommenLaboratory for the Analysis of Medicines, Center for Interdisciplinary Research on Medicines (CIRM), Quartier Hôpital, University of Liege, Liege, Belgium.
Anne-Catherine ServaisLaboratory for the Analysis of Medicines, Center for Interdisciplinary Research on Medicines (CIRM), Quartier Hôpital, University of Liege, Liege, Belgium.
Ines FradiLaboratory of Chemical, Pharmaceutical and Pharmacological Development of Drugs, Faculty of Pharmacy, University of Monastir, Monastir, Tunisia.
Marianne FilletLaboratory for the Analysis of Medicines, Center for Interdisciplinary Research on Medicines (CIRM), Quartier Hôpital, University of Liege, Liege, Belgium.
University of Liège · BEUniversity of Monastir · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this work, a monoclonal antibody, adalimumab, and an Fc-fusion protein, etanercept, were studied and compared to one of their biosimilars. Samples submitted to stress conditions (agitation and high temperature) were used for method development. The developed methods were also applied to samples reduced by beta-mercaptoethanol to evaluate their capability to distinguish the expected species. Capillary gel electrophoresis (CGE), reversed-phase liquid chromatography (RPLC), and size-exclusion chromatography (SEC) methods coupled with UV detection were used to analyze the biopharmaceuticals. Their complementarity was investigated. For further molecular weight determination, SEC-multi angle light scattering and RPLC-quadrupole time-of-flight were occasionally used. For adalimumab, a larger amount of fragments and aggregates was observed in the biosimilar compared with the reference product. For etanercept, more related species were found in the reference product. Those three separation techniques showed good complementarity. Indeed, RPLC enabled the separation of hydrophilic and hydrophobic degradation products. CGE provided good selectivity for several adalimumab fragments, and SEC was useful for the analysis of aggregates and certain fragments that cannot be separated by the other approaches. Moreover, those formulations were submitted to mild stress conditions (30°C, 300 rpm for 4 h) that mimic shipping conditions. No additional peak was found under these conditions for the two studied biopharmaceuticals.

Indexed as

adalimumabcapillary gel electrophoresisetanerceptreversed-phase liquid chromatographysize-exclusion chromatography

Identifiers

PMID34938718
PMCPMC8686473
OpenAlexW4200601334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.